Belzutifan with Von Hippel-Lindau (VHL)

Overview

About this study

The purpose of this study is to characterize the effectiveness of belzutifan for patients with VHL disease-associated RCC and/or CNS hemangioblastoma treated in real-world clinical practice. The primary effectiveness parameter includes tumor reductive procedures given the clinical importance of this parameter and association with subsequent morbidity and mortality of disease. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18 years of age.
  • Diagnosed with VHL disease based on a germline test or clinical diagnosis.
  • A decision has been made by the treating physician (at his/her discretion) to initiate the first belzutifan treatment (i.e., belzutifan 'new users'), within the prescribing conditions of the approved product label.
  • Signed informed consent prior to or within 30 days after the first initiation of belzutifan.

Exclusion Criteria:

  • Anti-cancer systemic therapy within 2 weeks prior to the index date.
  • Unable to consent to participate in the study.
  • History ofVHL disease-related metastasis or advanced cancer.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 06/20/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Pavel Pichurin, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mayowa Osundiji, M.B.B.S., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available